Zim Laboratories working capital

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023
198.91×198.91×182.37×143.68×98.59×
105.27×105.27×99.71×97.06×87.24×
157.18×157.18×143.40×128.40×106.91×
147.00×147.00×138.68×112.34×78.92×
4.65×4.38×5.84×5.39×4.97×
0.74×0.74×0.83×0.93×1.17×
8.48×8.48×3.38×0.94×1.54×
1.65×1.65×0.94×0.39×0.72×
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

ZIMLAB₹126.00

Zim Laboratories Limited

· Pharma & Health
₹ CrorePeersANUHPHRVALIANTLABAHCLALBERTDAVDWANBURYHALEOSLABSBAJAJHCARETHEMISMEDMcap ₹674 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Inventory Days (DIO)98.59143.68182.37198.91198.91
Receivable Days (DSO)87.2497.0699.71105.27105.27
Payable Days (DPO)106.91128.40143.40157.18157.18
Cash Conversion Cycle (days)78.92112.34138.68147.00147.00
Working Capital Turnover4.975.395.844.384.65
Asset Turnover1.170.930.830.740.74
Cash Conversion (CFO/Net Income)1.540.943.388.488.48
CFO/EBITDA0.720.390.941.651.65
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.